MDM2 and breast cancer: Consistent with our current findings and further supporting the importance of CRL in the regulation of tumor cell proliferation, the suppression of CRL activity using FBXO22 silencing inhibited cancer progression through targeting of HDM2 for degradation in breast cancer [12].